ActiveMax® Recombinant Mouse IFN-beta / IFNB1, Ile 22 - Asn 182 (Accession # P01575) was produced in human 293 cells (HEK293) at ACROBiosystems.
ActiveMax® Recombinant Mouse IFN-beta contains no "tag", and has a calculated MW of 19.9 kDa. The reducing (R) protein migrates as 27-33 kDa in SDS-PAGE due to glycosylation.
Less than 1.0 EU per μg by the LAL method.
>95% as determined by SDS-PAGE.
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally Trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
See Certificate of Analysis for reconstitution instructions and specific concentrations.
Avoid repeated freeze-thaw cycles.
No activity loss was observed after storage at:
In lyophilized state for 1 year (4°C); After reconstitution under sterile conditions for 3 months (-70°C).
Human type I interferons (IFNs) are a large subgroup of interferon proteins that help regulate the activity of the immune system. Interferons bind to interferon receptors. All type I IFNs bind to a specific cell surface receptor complex known as the IFN-α receptor (IFNAR) that consists of IFNAR1 and IFNAR2 chains. The IFN-β proteins are produced in large quantities by fibroblasts. They have antiviral activity that is involved mainly in innate immune response. Two types of IFN-β have been described, IFN-β1 (IFNB1) and IFN-β3 (IFNB3) (a gene designated IFN-β2 is actually IL-6). IFN-β1 is used as a treatment for multiple sclerosis as it reduces the relapse rate. Furthermore, IFN-β1 can bind to a IFNAR1-IFNAR2 heterodimeric receptor, and can also function with IFNAR1 alone and independently of Jak-STAT pathways.
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.